Inscrição na biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicou 4 edições por ano

ISSN Imprimir: 0893-9675

ISSN On-line: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Liquid Biopsies for Assessing Metastatic Melanoma Progression

Volume 21, Edição 1-2, 2016, pp. 141-154
DOI: 10.1615/CritRevOncog.2016016075
Get accessGet access

RESUMO

The field of genomic biomarkers in melanoma has evolved dramatically in the past few decades. Whereas much of the prior focus was on molecular assessment of tumor tissue, circulating tumor cells (CTCs), and cell-free circulating tumor DNA (ctDNA) as sources of a "liquid biopsy" in cancer patients provide promising potential as a method to assess tumor progression, identify targets for therapy, and evaluate clinical response to treatment. Blood biomarker assays have the advantage of being noninvasive, allow for dynamic evaluation of disease over a serial time frame, and help to address the issue of tissue sampling bias and tumor heterogeneity. However, there remains an assortment of technologies and techniques to isolate and detect CTCs and ctDNA and a standardized method has yet to be established. Despite these challenges, multiple studies have already demonstrated the clinical prognostic utility of blood-based genomic biomarker assays. With the advent of next-generation sequencing and genome-wide ctDNA analysis, this will undoubtedly lead to an improved understanding of tumor progression, help to identify new targets for treatment, and improve monitoring of treatment response and development of resistance.

CITADO POR
  1. Grzywa Tomasz M., Paskal Wiktor, Włodarski Paweł K., Intratumor and Intertumor Heterogeneity in Melanoma, Translational Oncology, 10, 6, 2017. Crossref

  2. Cheng Liang, Lopez-Beltran Antonio, Massari Francesco, MacLennan Gregory T, Montironi Rodolfo, Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine, Modern Pathology, 31, 1, 2018. Crossref

  3. Diefenbach Russell J., Lee Jenny H., Rizos Helen, Monitoring Melanoma Using Circulating Free DNA, American Journal of Clinical Dermatology, 20, 1, 2019. Crossref

  4. Helgadottir Hildur, Rocha Trocoli Drakensjö Iara, Girnita Ada, Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment, Frontiers in Oncology, 8, 2018. Crossref

  5. Burnier Julia V., Mastromonaco Christina, Lasiste Jade Marie, Burnier Miguel N., Animal Models in Uveal Melanoma, in Clinical Ophthalmic Oncology, 2019. Crossref

  6. Bustos Matias A., Tran Kevin D., Rahimzadeh Negin, Gross Rebecca, Lin Selena Y., Shoji Yoshiaki, Murakami Tomohiro, Boley Christine L., Tran Linh T., Cole Hunter, Kelly Daniel F., O’Day Steven, Hoon Dave S. B., Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis, Cancers, 12, 6, 2020. Crossref

  7. Marczynski Gabriella Taques, Laus Ana Carolina, dos Reis Mariana Bisarro, Reis Rui Manuel, Vazquez Vinicius de Lima, Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients, Scientific Reports, 10, 1, 2020. Crossref

  8. Bustos Matias A., Gross Rebecca, Rahimzadeh Negin, Cole Hunter, Tran Linh T., Tran Kevin D., Takeshima Ling, Stern Stacey L., O’Day Steven, Hoon Dave S. B., A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients, Cancers, 12, 11, 2020. Crossref

  9. Schank Timo E., Forschner Andrea, Sachse Michael Max, Dimitrakopoulou-Strauss Antonia, Sachpekidis Christos, Stenzinger Albrecht, Volckmar Anna-Lena, Enk Alexander, Hassel Jessica C., Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival, Cancers, 13, 11, 2021. Crossref

  10. Muluhngwi Penn, Valdes Jr Roland, Fernandez-Botran Rafael, Burton Eric, Williams Brian, Linder Mark W, Cell-free DNA diagnostics: current and emerging applications in oncology, Pharmacogenomics, 20, 5, 2019. Crossref

  11. Fattore Luigi, Ruggiero Ciro Francesco, Liguoro Domenico, Castaldo Vittorio, Catizone Angiolina, Ciliberto Gennaro, Mancini Rita, The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma, Frontiers in Oncology, 11, 2021. Crossref

  12. Pendley Bradford D., Lindner Erno, Medical Sensors for the Diagnosis and Management of Disease: The Physician Perspective, ACS Sensors, 2, 11, 2017. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain